Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of CS0159 Tablets in Subjects With Mild (Child-Pugh: Class A), Moderate (Child-Pugh: Class B) Hepatic Impairment, and Normal Hepatic Function

NCT06888115 is registered in ClinicalTrials.gov with Cascade Pharmaceuticals, Inc as lead sponsor.

NCT NCT06888115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06888115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of CS0159 Tablets in Subjects With Mild (Child-Pugh: Class A), Moderate (Child-Pugh: Class B) Hepatic Impairment, and Normal Hepatic Function
Lead sponsor
Cascade Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Completed
Start date
March 13, 2025
Completion date
June 3, 2025
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis